Loukia Lili

Dr. Loukia Lili


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
NMNozomi Matsuura
Nozomi Matsuura
MKMasaya Kanayama
Masaya Kanayama
YWYuta Watanabe
Yuta Watanabe
HYHirokazu Yamada
Hirokazu Yamada
LLLoukia Lili
Loukia Lili
ATAkira Torii
Akira Torii
Background/Objectives: Prebiotics and probiotics have been reported to improve symptoms of irritable bowel syndrome (IBS). Nevertheless, the effects of prebiotics/probiotics can vary depending on the IBS subtypes. The purpose of this study was to investigate the effects of personalized prebiotic and probiotic supplements based on intestinal microbiota and IBS subtypes in patients. Methods: Patients with diarrhea-type IBS (IBS-D), constipation-type IBS (IBS-C), and mixed-type IBS (IBS-M) were enrolled (n = 40 per group; total: n = 120). Personalized prebiotic and probiotic supplements were determined according to the IBS subtypes and intestinal microbiota. The patients received supplements for 4 weeks. The primary outcome was the change in the IBS-severity scoring system from baseline to week 4. Results:The IBS-severity scoring system significantly decreased in all patients (−38.0 [95% confidence interval (CI): −53.6, −22.4]; p < 0.001), in patients with IBS-D (−44.5 [95% CI: −70.6, −18.5]; p = 0.004) and IBS-C (−51.2 [95% CI: −79.4, −22.9]; p = 0.002), but not in those with IBS-M (−20.0 [95% CI: −48.0, 8.1]; p = 0.47). In this study, no serious adverse events were observed that had a causal relationship with the intervention. Conclusions: In conclusion, personalized prebiotic and probiotic supplements selected according to individual intestinal microbiota and IBS subtype may alleviate the severity of IBS symptoms, particularly in patients with IBS-C and IBS-D.

5 December 2023 in Heliyon
Verified
Journal Article
Open access
LLLoukia Lili
Loukia Lili
CMCem Meydan
Cem Meydan
NRNate Rickard
Nate Rickard
BZBodi Zhang
Bodi Zhang
The hematologic and metabolic benefits of high altitude exposure have been extensively studied in athletes due to their promising performance enhancing effects. However, despite the increased research and development of various high altitude protocols for achieving peak performance, the reproducibility of the results at the individual level remains sparse. To systematically address this limitation and establish a more effective method to achieve consistent results at the individual level, we conducted a multi-dimensional study of one elite endurance athlete in two Phases. In Phase 1, we applied the standard protocol of LHTH (Live-High-Train-High) using a commercially available, at-home, normobaric, high altitude simulation tent under the SHTL (Sleep-High-Train-Low) model. Then, we developed the athlete's personalized protocol for peak hematologic parameters during their off-season. This protocol determined the exact total high altitude exposure time required to achieve peak hematologic parameters, which in the case of this athlete, amounted to 45 nights with approximately 8hrs per night. In Phase 2, we replicated the Phase 1 protocol during the athlete's in-season and observed the same or even higher hematologic and metabolic benefits compared to Phase 1. During both phases, we collected thousands of multi-dimensional data points to ensure that the athlete's lifestyle and environmental factors remained stable, and to increase the likelihood that physiological changes resulted primarily from the high altitude exposure. The data trends in both Phases validated that, for this athlete, hematologic measures such as red blood cell count, hematocrit, and hemoglobin, as well as electrolyte content, body weight and gut microbiome composition improved to their personal best values after a total of approximately 15 days of high altitude exposure (45 nights with roughly 8hrs per night totaling 360hrs or 15days). These improvements did not occur after the 21 days recommended by the LHTH protocol highlighting the significance of personalization in high altitude protocols that are designed for peak performance parameters. Therefore, to maximize the benefits in hematologic and other metabolic values and thus increase muscle oxygen supply and peak aerobic capacity through high altitude exposure, each athlete may require a unique total duration of high altitude exposure tailored to their individual physiology. This duration must be determined by their specific response in hematologic peaking. Therefore, initially establishing a personalized protocol for an athlete by determining their required total duration of high altitude exposure for peak hematologic values during their off-season and applying this protocol during their in-season phase may lead to more successful and reproducible benefits compared to following a generalized protocol alone.

12 September 2025 in Molecular Nutrition & Food Research
Verified
Journal Article
Open access
LLLoukia Lili
Loukia Lili
SSSheena Smith
Sheena Smith
LKLaura Kunces
Laura Kunces
RARiva Antonella
Riva Antonella
PAPietro Allegrini
Pietro Allegrini
BZBodi Zhang
Bodi Zhang
In preventive healthcare, the demand for systematic identification of wellness‐promoting natural compounds is rising. Quercetin, a phenolic compound found in various fruits and vegetables, is known for its antioxidant and anti‐inflammatory properties, improving lipid profiles and metabolic dysfunctions in conditions like Type 2 diabetes and NAFLD. This study applies a novel adaptation of an in‐silico drug repurposing methodology to quercetin, analyzing a gene expression signature library of over 800 diseases and 30 quercetin‐related conditions to prioritize molecular targets. Our findings revealed a strong computational link between quercetin and hypercholesterolemia. To validate this, we conducted a proof‐of‐concept clinical study using a high‐bioaccessibility quercetin formulation (Quercefit TM ) in healthy adults with borderline metabolic profiles, confirming health benefits. This study highlights quercetin's known potential in managing hypercholesterolemia and demonstrates the power of computational methods in advancing natural compound discovery and repositioning. The integration of in‐silico predictions with human studies could pave the way for more precise or alternative use of bioactive compounds in dietary supplements.